Literature DB >> 3335336

Quinolones: their uses in geriatric infections.

N M Gantz1.   

Abstract

The quinolones represent a unique class of drugs which offer a new option for clinicians to treat a wide variety of infections in the elderly patient. Whereas the emergence of resistance is a major problem with the older quinolones such as nalidixic acid, this appears to be a minor problem with the new fluoroquinolones such as norfloxacin or ciprofloxacin. These drugs are bactericidal and are well-absorbed orally. Parenteral preparations should be available in the future. The drugs are particularly active against gram-negative bacilli, including Pseudomonas aeruginosa. The fluoroquinolones are less active against pneumococci, Group A streptococci, Pseudomonas cepacia, and most anaerobes. The drugs appear potentially useful to treat urinary tract infections caused by multiply resistant pathogens, prostatitis, gastrointestinal pathogens, osteomyelitis, gram-negative pneumonia, and sexually transmitted diseases. Adverse effects occur in approximately 10% of patients and include gastrointestinal symptoms and potential central nervous system toxicity in patients receiving theophylline, non-steroidal drugs, or caffeine. The oral quinolones may reduce the costs of treating serious infections in the elderly.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335336

Source DB:  PubMed          Journal:  Geriatrics        ISSN: 0016-867X


  3 in total

1.  Case report: severe neurologic reaction to ciprofloxacin.

Authors:  W MacLeod
Journal:  Can Fam Physician       Date:  2001-03       Impact factor: 3.275

Review 2.  The use of oral fluoroquinolones in nursing home patients.

Authors:  T M File; J S Tan
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

3.  Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials.

Authors:  Vincent T Andriole; Daniel C Haverstock; Shurjeel H Choudhri
Journal:  Drug Saf       Date:  2005       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.